Research Contributions

The following research contributions have advanced and improved the treatment of MS patients:

  • Plasma exchange for the treatment of acute devastating attacks of MS
  • Oligodendrocyte as the initial site of injury
  • Four distinct pathologic patterns that respond differently to treatment
  • Pattern II lesions have immunoglobulin and complement deposition; these patients respond uniquely to plasma exchange
  • Antibody to aquaporin 4 that distinguishes neuromyelitis optica from MS from MS
  • FDA approval of interferon beta to reduce exacerbations based, in part, on viral models of MS established at Mayo
  • Disability, impairment, handicap and genetic studies in the prevalence and incidence cohorts of MS in Olmsted County (1905-2008)
  • Human monoclonal antibody to repair the CNS will soon enter Phase I clinical trials at Mayo
  • Clinical trials showing that aspirin reduces fatigue, the most common disabling feature of MS
  • CD8+ T cells and perforin as primary mediators of injury